TrialIntensive care medicine2019

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab.

Richard S Hotchkiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.